Hepatic arterial infusion chemotherapy in combination with pegylated interferon-α-2b for advanced hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 59, Issue 114, 2012, Pages 533-537

  Okita, Kohsuke ^a   Yamasaki, Takahiro ^a   Hamabe, Satoe ^a   Saeki, Issei ^a   Harima, Yohei ^a   Terai, Shuji ^a   Sakaida, Isao ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced hepatocellular carcinoma; Hepatic arterial infusion chemotherapy; Interferon 2b; Pegylated interferon 2b

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINATE CALCIUM; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ADVANCED CANCER; APPETITE DISORDER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; FATIGUE; FEMALE; FEVER; HUMAN; INTRON; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; ULCER;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84860574607     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10013     Document Type: Article

References (25)

1. El-Serag HB, Marrero JA, Rudolph L, Reddy KR: Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134:1752-1763. (Pubitemid 351615415)
2. Ebara M, Okabe S, Kita K, et al.: Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol 2005; 43:458-464. (Pubitemid 41111427)
3. Matsui O, Kadoya M, Yoshikawa J, et al.: Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 1993; 188:79-83. (Pubitemid 23183103)
4. Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Okita K: Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma. Cancer 2001; 91:1342-1348. (Pubitemid 32267046)
5. Todo S, Furukawa H: Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004; 240:451-459; discussion 459-461.
6. Leung TW, Tang AM, Zee B, Yu SC, Lai PB, Lau WY, Johnson PJ: Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002; 94:421-427. (Pubitemid 34081372)
7. Chung YH, Song IH, Song BC, et al.: Combined therapy consisting of intra-arterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88:1986-1991.
8. Llovet JM, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
9. Llovet JM, Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48(1):S20-37.
10. Kudo M: Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 2008; 75(1):1-12.
11. Yamasaki T, Kurokawa F, Shirahashi H, et al.: Novel arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. Hepatol Res 2002; 23:7-17. (Pubitemid 36113463)
12. Yamasaki T, Kurokawa F, Takami T, et al.: Arterial infusion chemotherapy using cisplatin, 5-fluorouracil, and isovorin for patients with advanced hepatocellular carcinoma, pilot study: Is a high dose of the biochemical modulator effective? Hepatol Res 2003; 27:36-44. (Pubitemid 37168650)
13. Yamasaki T, Kimura T, Kurokawa F, et al.: Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol 2005; 40:70-78. (Pubitemid 40796335)
14. Takaki-Hamabe S, Yamasaki T, Saeki I, Harima Y, Okita K, Terai S, Sakaida I: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: is the addition of subcutaneous interferon-alpha-2b beneficial? Hepatol Res 2009; 39:223-230.
15. O'Connell MJ: A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 1989; 63:1026-1030.
16. Ota H, Nagano H, Sakon M, et al.: Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005; 93:557-564. (Pubitemid 43079999)
17. Obi S, Yoshida H, Toune R, et al.: Combination therapy of intra-arterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106:1990-1997. (Pubitemid 43673215)
18. Yano H, Ogasawara S, Momosaki S, et al.: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int 2006; 26:964-975. (Pubitemid 44323415)
19. Oken MM, Creech RH, Tormey DC, et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655. (Pubitemid 13149996)
20. Kudo M, Chung H, Osaki Y: Prognostic staging system for hepatocellular carcinoma (CLIP score): Its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38:207-215. (Pubitemid 36527122)
21. Common Terminology Criteria for Adverse Events: v3.0.
22. Kaplan E, Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53:457-481.
23. Glue P, Fang JW, Rouzier-Panis R, et al.: Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68:556-567.
24. Eguchi H, Nagano H, Yamamoto H, et al.: Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 2000; 6:2881-2890. (Pubitemid 30482131)
25. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236. (Pubitemid 43112690)